ceftibuten + VNRX-7145

VNRX-7145 is an orally bioavailable, broad-spectrum boronic acid beta-lactamase inhibitor (BLI) developed by Venatorx Pharmaceuticals. It serves as a prodrug of the active inhibitor VNRX-5232. VNRX-7145 is designed to be administered in combination with a partner beta-lactam antibiotic, specifically ceftibuten, to address the clinical challenge of multi-drug resistant (MDR) Gram-negative bacteria. The compound targets a wide range of beta-lactamases, including Class A (ESBLs, KPC), Class C (AmpC), and Class D (OXA-48) enzymes. By inhibiting these enzymes, VNRX-7145 restores the antibacterial activity of ceftibuten against resistant strains, including Carbapenem-Resistant Enterobacteriaceae (CRE). The combination is primarily being developed as an oral treatment option for complicated urinary tract infections (cUTI) and other serious infections that currently necessitate intravenous therapy.

Other names

ceftibuten/VNRX-7145VNRX-7145 + ceftibuten